A modeling study projected that HPV vaccination programs for adults aged 27 to 45 years could benefit subgroups at higher risk for HPV, but overall, the approach is more costly and less effective than ...
In this modeling study, the cost-effectiveness and number needed to vaccinate of mid-adult human papillomavirus (HPV) vaccination improved when limited to those at higher risk for acquiring HPV ...
According to DelveInsight’s analysis, the human papillomavirus market is anticipated to increase during the forecast period (2024–2034), owing to the launch of emerging therapies and healthcare ...